Current status of bispecific antibody-mediated immunotherapy for hematologic malignancies
10.13303/j.cjbt.issn.1004-549x.2021.05.030
- VernacularTitle:双特异性抗体介导的血液恶性肿瘤免疫治疗研究进展
- Author:
Xiaojuan PANG
1
;
Guochuang CHEN
1
;
Ping CHEN
1
;
Yingjie WU
2
,
3
;
Yiwu XIE
1
Author Information
1. Syno Minicircle Biotechnology Co. Ltd., Shenzhen 518107, China
2. Shandong Provincial Hospital, Shandong First Medical University
3. Shandong Animal Models Center, Shandong First Medical University
- Publication Type:Journal Article
- Keywords:
bispecific antibody;
hematologic malignancy;
immunotherapy;
tumor-associated antigen
- From:
Chinese Journal of Blood Transfusion
2021;34(5):560-566
- CountryChina
- Language:Chinese
-
Abstract:
Significant advances have been made in cancer immunotherapy recently, of which, bispecific antibodies (BsAbs), through bridging, redirecting and activating immune effector cells to kill cancer cells, are attracting increasing attention.Since the anti-CD19 and anti-CD3 BsAb, blinatumomab, was approved in 2014 by the FDA for the treatment of acute lymphoblastic leukemia, preclinical and clinical research with immune-cell-redirecting BsAbs have been fast growing in the area of hematologic malignancies. This review summarizes the current scientific and clinical investigation of BsAbs targeting different tumor-associated antigens from B lymphocytes, plasma cells and myeloid cells, covering three most common blood cancers, namely, lymphoma, multiple myeloma and leukemia. Further development for better therapeutic benefits and lower adverse events, are continuously being pursued, in particular, looking for more specific tumor antigens, optimizing antigen-antibody affinities, extending the half-life of BsAbs and redirecting different immune effector cells, whose breakthroughs and opportunities are soon to be delivered for the management of hematologic malignancies.
